Overview

Quotient Bioscience Group Limited (“Quotient”), a leading European provider of analytical and safety evaluation services and products for bioscience and sport, is pleased to announce that it has acquired Pharmaceutical Profiles Group Limited (“Pharmaceutical Profiles”).

Pharmaceutical Profiles is a leading provider of specialist Phase I drug development services to the global pharmaceutical and biotechnology industries, including the development of optimized oral, intravenous, and inhaled clinical dosage forms.

Pharmaceutical Profiles will become an important member of Quotient’s Drug Development Services Group – Quotient Bioresearch.

Significance

The combination with Pharmaceutical Profiles will offer Quotient Bioresearch a unique opportunity to provide its clients with a truly integrated metabolic sciences service offering, spanning radio synthesis through to human AME studies, while also building on Pharmaceutical Profiles’ unique position in accelerated clinical formulation development.

These integrated approaches should allow Quotient’s clients to realize major efficiencies prior to moving into late phase drug development, whilst making Quotient Bioresearch a world leader in radiolabeled (“14C”) drug development.

Pharmaceutical Profiles represents the fifth acquisition to date for Quotient, which was established in early 2007, and shifted its focus to acquisition-led growth following a £35 million equity fundraising with TA Associates.

Crosstree’s Role

Crosstree Capital Partners acted as the exclusive financial advisor for Pharmaceutical Profiles Limited.